Approval · Notice of Compliance 34167 · 2024
TEVA-ELETRIPTAN: Notice of Compliance 34167
Issued October 9, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34167
- Date
- October 9, 2024
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to package labels. Update to package insert
- Canadian reference product
- REPLAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-ELETRIPTAN | Not yet assigned | — |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB